Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1615/critrevoncog.v17.i3.10 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preface to "newer techniques and tools lead to a paradigm shift in the diagnosis and management of upper tract urothelial carcinoma".
Transl Androl Urol
September 2024
Department of Urology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Preface to "Complex Penile Prosthesis Surgery".
Transl Androl Urol
September 2024
Section of Urology, Dartmouth-Hitchock Medical Center, Lebanon, NH, USA.
Preface to the special issue "Neuroimmunology".
J Neurochem
October 2024
Department of Neuroscience, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
This preface introduces the Special Issue on Neuroimmunology in the Journal of Neurochemistry. The basis of neuroimmunology is to understand functional interactions between cells of the immune system and the central nervous system (CNS). These cells communicate across systems because they share signaling molecules and corresponding receptors.
View Article and Find Full Text PDFPreface for special issue: "Emerging strategies, technologies, and approaches for the next generation ADCs".
Xenobiotica
August 2024
BioAnalytical Sciences, Genentech Inc, South San Francisco, CA, USA.
1. Antibody-drug conjugates (ADCs) represent an advanced category of biotherapeutic agents, typically consisting of an antibody bound to a biologically-active cytotoxic agent. Since the first ADC, Mylotarg, was approved in 2000, there have been fifteen ADCs sanctioned to date, with thirteen receiving approval from the FDA for the treatment of a variety of cancers, including blood malignancies and solid tumors.
View Article and Find Full Text PDFPrognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
Eur J Cancer
September 2024
Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
Background: The monarchE and NATALEE trials demonstrated the benefit of CDK4/6 inhibitor (CDK4/6i) therapy in adjuvant breast cancer (BC) treatment. Patient selection, based on clinical characteristics, delineated those at high (monarchE) and high/intermediate recurrence risk (NATALEE). This study employed a historical patient cohort to describe the proportion and prognosis of patients eligible for adjuvant CDK4/6i trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!